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Abstract
Background—The hepatitis G virus
(HGV), a recently identified member of
the Flaviviridae family, can cause chronic
infection in man but the role of this agent
in chronic liver disease is poorly under-
stood.
Aims—To evaluate the prevalence and
meaning of HGV infection in a large series
of patients with chronic liver disease.
Subjects—Two hundred volunteer blood
donors, 179 patients with chronic hepatitis
C, 111 with chronic hepatitis B, 104 with
alcoholic liver disease, 136 with hepatocel-
lular carcinoma, and 24 with cryptogenic
chronic liver disease were studied.
Methods—HGV RNA was investigated in
serum samples by reverse transcription
and polymerase chain reaction amplifica-
tion of the 5' non-coding region of HCV
and hybridisation to a specific probe. The
main features of HGV RNA seropositive
and seronegative patients were compared.
Results—The prevalence of HGV infection
was 3% in blood donors, 7% in chronic
hepatitis C, 8% in chronic hepatitis B, 2%
in alcoholic liver disease, 4% in hepatocel-
lular carcinoma, and 8% in cryptogenic
chronic liver disease. HGV infected pa-
tients tended to be younger than non-
infected patients but no diVerences
concerning sex, possible source of infec-
tion, clinical manifestations, biochemical
and virological parameters, or severity of
liver lesions were found.
Conclusions—The prevalence of HGV in-
fection in chronic liver disease seems to be
relatively low in our area. Infection with
HGV does not seem to play a significant
pathogenic role in patients with chronic
liver disease related to chronic HBV or
HCV infection or to increased alcohol
consumption, or in those with cryptogenic
chronic liver disease.
(Gut 1998;42:107–111)
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The hepatitis G virus (HGV) is a recently
identified member of the Flaviviridae family
distantly related to hepatitis C virus (HCV).1 2
This virus can be transmitted eYciently by
blood transfusion and by other parenteral
mechanisms2–5 and transient and long lasting
infections with HGV have been documented in
man.2 4
HGV RNA sequences have been detected in
a high proportion of volunteer blood donors.2 6
HGV RNA positive donors may present with
minor increases in serum alanine aminotrans-
ferase (ALT) but at least 50% of them do not
present with any evidence of liver disease. On
this basis, HGV does not appear to be highly
pathogenic.
Infection with HGV has, however, also been
detected in a high proportion of patients with
idiopathic fulminant hepatitis,7 8 suggesting
that HGV may be highly pathogenic in some
cases. This possibility is still open to question
since other studies have not disclosed a signifi-
cant prevalence of HGV infection in this
condition.9 10
There is also controversy about the role of
HGV infection in the pathogenesis of chronic
liver disease. Preliminary surveys of patients
with chronic liver disease showed that HGV is
often detected in patients chronically infected
with other hepatotropic viruses such as the
hepatitis B virus (HBV) or HCV but more
rarely in patients with cryptogenic liver
disease.2 11 12 Some studies have however found
a relatively high prevalence of HGV infection in
patients with cryptogenic chronic hepatitis,
suggesting that this virus may be important in
this condition.13 14
To elucidate further the pathogenic role of
HGV in chronic liver disease we investigated
the prevalence of HGV infection and its
associated features in 554 patients with diVer-
ent chronic liver diseases including represent-
ative series of patients with alcoholic liver
disease and hepatocellular carcinoma.
Patients and methods
PATIENTS
Five hundred and fifty four patients with
chronic liver disease and 200 consecutive first
donation volunteer blood donors were studied.
According to clinical, serological, and his-
topathological features, patients were separated
into the following categories.
Chronic hepatitis C
This group included 179 patients (109 male
and 70 female; mean age 50 years, range
19–83). Chronic hepatitis C was assessed by
sustained elevation of ALT, histologically
proved chronic inflammation of the liver, and
positive tests for anti-HCV antibodies and for
HCV-RNA in serum. Other causes of chronic
liver disease were excluded.
Chronic hepatitis B
This group included 111 patients (92 male and
19 female; mean age 41 years, range 14–69)
with chronic hepatitis B virus infection, as
assessed by long lasting hepatitis B surface
(HBsAg) antigenaemia and elevated ALT.
Liver biopsy was performed in 71 cases.
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Alcoholic patients
This group included 104 patients (70 male and
34 female; mean age 43 years, range 22–76)
who had consumed more than 80 g of ethanol
per day for at least five years. HBsAg and anti-
HCV were negative in all cases. Liver biopsy
showed minimal abnormalities or fatty infiltra-
tion in 43 (41%), fatty infiltration and fibrosis
in 14 (13.5%), alcoholic hepatitis in 23
(22.1%), hepatic cirrhosis in 21 (20.2%), and
chronic hepatitis in three (3%).
Hepatocellular carcinoma
This group included 136 patients (91 male and
45 female; mean age 64 years, range 40–93)
with hepatocellular carcinoma and underlying
cirrhosis. The diagnosis of hepatocellular
carcinoma was based on data from imaging
techniques—ultrasonography, computed tom-
ography, and/or hepatic arteriography—and
confirmed by histopathological and/or cyto-
logical examinations. The aetiology of pre-
existing cirrhosis was known in 125 cases.
Cryptogenic chronic liver disease
This group included 24 patients (12 male and
12 female; mean age 45 years, range 19–75)
years. All presented with abnormalities of liver
function tests consisting mainly of elevation of
aminotransferase serum levels 1.5 times above
the upper normal limit lasting for at least one
year. None were obese or alcoholic, and all
denied use of potentially hepatotoxic drugs. All
had negative tests for HBsAg, anti-HCV, HCV
RNA, and autoantibodies (antinuclear, antis-
mooth muscle, antimitochondrial, and antiliver
and kidney microsomes). Serum levels of iron,
ferritin, caeruloplasmin, and á1-antitripsin
were normal in all cases. Liver biopsy showed
minimal changes in 10 cases, fatty liver in four,
minimal cholestasis in two, chronic hepatitis in
two, portal and periportal fibrosis in two, and
micronodular cirrhosis in four.
Blood donors
Two hundred consecutive volunteer blood
donors (114 male and 86 female; mean age 39
years, range 18–65) were studied at the time of
their first donation.
SEROLOGICAL METHODS
HBsAg, anti-HCV, and anti-HDV were tested
with commercially available enzyme linked
immunosorbent assay (ELISA) kits. HBV-
DNA in serum was investigated by polymerase
chain reaction (PCR) amplification of HBV
core sequences according to a simplified
protocol reported previously.15
HCV RNA in serum was determined by
reverse transcription (RT) and amplification by
nested PCR of the 5' non-coding region
(5'NCR) region of HCV, as described
previously.16 HCV RNA serum levels were
measured by a competitive PCR method
recently developed in our laboratory.17 18 HCV
genotype was determined according to
Okamoto et al19 with some modifications, as
described previously.20
HGV RNA in serum was determined as
described previously.10 18 In brief, RNA was
extracted from 140 µl of serum using a
commercially available kit (QiAmp, Qiagen,
Hilden, Germany). Complementary DNA was
synthesised from 15 µl of extracted RNA by 60
minutes incubation at 37°C with 300 U of
Moloney leukaemia virus reverse transcriptase
(Gibco-BRL, Gaithersburg, Maryland, USA),
random primers, and 20 U of ribonuclease
inhibitor in a final volume of 30 µl of RT buffer
(50 mMTris-HCl, pH 8.3, 75 mMKCl, 3 mM
MgCl2, 10 mMDTT, 0.01% gelatine, 200 mM
each deoxynucleotide). Specific PCR amplifi-
cation and hybridisation of the 5'NCR of the
HGV genome was carried out using a commer-
cial kit (Hepatitis G virus-Primer and capture
probe set, Boehringer, Mannheim GmbH,
Mannheim, Germany) according to the manu-
facturer’s instructions. One positive and three
negative controls were included in each run.
The background signal of negative controls
ranged between 0.084 and 0.113. Samples giv-
ing a signal five times above the mean
background signal were considered positive.
Results were accepted on agreement on
repeated testing.
STATISTICAL ANALYSIS
Comparisons between groups were made by
the ÷2 or Fisher’s exact test for categorical vari-
ables and by the Mann-Whitney test or
Student’s t test when appropriate for quantita-
tive variables. A p value less than 0.05 was con-
sidered significant.
Results
HGV INFECTION IN BLOOD DONORS
HGV RNA was detected in six of 200 blood
donors (3%). Anti-HCV was positive in two
(1%) and HBsAg in one (0.5%).HGV infected
donors were younger than non-infected donors
(27 (5) versus 39 (14) years, p=0.03). None of
the HGV infected donors had past history or
clinical evidence of liver disease. ALT values
were similar in HGV infected (32 (8) IU/l) and
non-infected donors (29 (14) IU/l). A minimal
elevation of ALT (45 IU) was detected in one
of six (17%) HGV infected and in 28 of 194
(14%) non-infected donors.
HGV INFECTION IN PATIENTS WITH CHRONIC
HEPATITIS C
HGV RNA sequences were found in 12 of 179
patients (6.7%). Although the prevalence of
HGV infection in this group was higher than in
blood donors the diVerence did not reach sta-
tistical significance. No significant diVerences
between HGV infected and non-infected pa-
tients were observed concerning the demo-
graphic features, the presumed source of infec-
tion, the biochemical or haematological
abnormalities, the degree of severity of liver
lesions, the infecting HCV genotype, or the
level of HCV viraemia (table 1).
HGV INFECTION IN PATIENTS WITH CHRONIC HBV
INFECTION
HGV RNA was detected in nine of 111
patients (8.1%). Although the prevalence of
HGV infection in this group was higher than in
blood donors the diVerence was not statisti-
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cally significant. As shown in table 2 compari-
son of HGV infected and non-infected patients
did not show significant diVerences concerning
demographic features, biochemical and hae-
matological abnormalities, severity of liver
lesions, level of detectable HBV replication, or
infection with other hepatotropic viruses such
as HDV and HCV. The presumed source of
infection was also similar. However, a high rate
of HGV infection (four of 10) was observed
among HBV infected male homosexuals.
HGV INFECTION IN PATIENTS WITH ALCOHOLIC
LIVER DISEASE
HGV RNA was detected in two of 104 patients
(1.9%). Statistical analysis was not possible
due to the small number of HGV-RNA positive
patients. One was a 39 year old woman without
clinical evidence of liver disease and slightly
abnormal liver function tests (serum aspartate
aminotransferase (AST) 60 IU/l, ALT 38 IU/l,
alkaline phosphatase 149 IU/l, ã-glutamyl
transferase 76 IU /l, bilirubin 0.8 mg/dl, serum
albumin 42 g/l, prothrombin time 100%) in
whom liver biopsy showed mild fatty infiltra-
tion of the liver. The other was a 51 year old
man with hepatic cirrhosis and abnormal liver
function tests. None had a history of blood
transfusion or intravenous drug misuse. Eight
of 102 HGV-RNA negative patients had
received blood transfusions in the past.
HGV INFECTION IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA
HGV RNA was detected in five of 136 patients
(3.7%). This prevalence is almost identical to
that found in blood donors. HGV infected
patients tended to be younger than non-
infected patients. A history of blood transfu-
sion prior to diagnosis of liver disease was more
frequent in HGV infected patients. However,
statistical analysis did not show significant dif-
ferences between the two groups of patients
concerning demographic features, presumed
aetiology of underlying cirrhosis, presumed
source of infection, or haematological and bio-
chemical features (table 3). HGV-RNA was
detected in association with HCV infection in
four of the five cases.
HGV INFECTION IN PATIENTS WITH CRYPTOGENIC
CHRONIC LIVER DISEASE
HGV RNA was detected in two of 24 patients
(8.3%). One was an asymptomatic 55 year old
woman with slight ALT elevation lasting for
seven years after recovery from an episode of
fulminant hepatitis of unknown aetiology. The
patient had received blood products at that
time. The other was a 19 year old man with
abnormal liver function tests in whom liver
biopsy showed evidence of chronic hepatitis
with mild activity and minimal fibrosis. A pos-
sible source of infection was not identified in
this patient. Further analysis was not possible
due to the small number of HGV infected
patients detected in this group.
Discussion
HGV, or GBV-C, is a recently identified mem-
ber of the Flaviviridae family that can cause
Table 1 Baseline features of patients with chronic hepatitis C according to the presence or
absence of HGV-RNA sequences in serum
Characteristics
HGV-RNA
negative (n=167)
HGV-RNA
positive (n=12) p Value
Age (y) 50 (14) 49 (17) NS
Sex (male/female) 102/65 7/5 NS
Presumed source of infection NS
Blood transfusion 51 (30%) 3 (25%)
Addiction to i.v. drugs 15 (9%) 2 (17%)
Unknown 101 (61%) 7 (58%)
WBC count (×109/l) 5.6 (1.8) 4.1 (2.3) NS
Platelet count (×109/l) 152 (55) 125 (65) NS
AST (IU/l) 92 (61) 95 (80) NS
ALT (IU/l) 151 (115) 186 (151) NS
ã-glutamyl transferase (IU/l) 52 (44) 32 (15) NS
Bilirubin (mg/dl) 0.9 (1.01) 1.0 (0.7) NS
Degree of histological severity NS
Mild hepatitis 55 (33%) 2 (16%)
Moderate hepatitis 50 (30%) 4 (33%)
Severe hepatitis 18 (11%) 2 (16%)
Cirrhosis 44 (26%) 4 (33%)
Virological features
Genotype 1b 131 (80%) 8 (67%) NS
Other genotypes 33 (20%) 4 (33%) NS
HCV viraemia (copies/ml ×106) 0.418 (0.873) 1.105 (1.719) NS
Quantitative variables are expressed as mean (SD). Categorical variables are expressed as n (%).
Table 2 Baseline features of patients with chronic HBV infection according to the presence
or absence of HGV-RNA sequences in serum
Characteristics
HGV-RNA
negative (n=102)
HGV-RNA
positive (n=9) p Value
Age (y) 41 (13) 36 (5) NS
Sex (male/female) 86/16 6/3 NS
Presumed source of infection NS
Blood transfusion 1 (1%) 1 (11%)
Addiction to i.v. drugs 2 (2%) 1 (11%)
Intrafamilial 19 (19%) 1 (11%)
Male homosexuality 6 (5%) 4 (44%)
Unknown 74 (67%) 2 (22%)
WBC count (×109/l) 5.9 (1.8) 5.5 (1.7) NS
Platelet count (×109/l) 156 (47) 163 (61) NS
AST (IU/l) 70 (54) 63 (29) NS
ALT (IU/l) 125 (118) 111 (91) NS
ã-glutamyl transferase (IU/l) 45 (47) 28 (7) NS
Bilirubin (mg/dl) 0.8 (0.3) 0.6 (0.4) NS
Degree of histological activity NS
Mild hepatitis 16 (23%) 2 (29%)
Moderate hepatitis 22 (31%) 1 (14%)
Severe hepatitis 22 (31%) 3 (43%)
Liver cirrhosis 8 (11%) 1 (14%)
Other virological markers NS
HBV-DNA positive 64 (63%) 4/9 (44%) NS
Anti-HDV positive 2 (2%) 1/9 (11%) NS
Anti-HCV positive 11 (13%) 2/9 (22%) NS
Quantitative variables are expressed as mean (SD). Categorical variables are expressed as n (%).
Table 3 Baseline features of patients with liver cirrhosis and hepatocellar carcinoma
according to the presence or absence of HGV-RNA sequences in serum
Characteristics
HGV-RNA
negative (n=131)
HGV-RNA
positive (n=5) p Value
Age (y) 64 (9) 57 (9) NS
Sex (male/female) 88/43 3/2 NS
Aetiology of cirrhosis NS
Alcoholic 11 (8%) 1 (20%)
HCV infection 78 (60%) 2 (40%)
HBV infection 4 (3%) 0
HCV and HBV infection 5 (4%) 0
Alcoholic and HCV infection 20 (15%) 1 (20%)
Alcoholic and HBV infection 2 (2%) 0
PBC and HCV infection 0 1 (20%)
Cryptogenic 11 (8%) 0
Presumed source of infection NS
Blood transfusion 35 (27%) 4 (80%)
Unknown 96 (73%) 1 (20%)
WBC count (×109/l) 5.9 (4.1) 5.4 (2.4) NS
Platelet count (×109/l) 107 (53) 107 (58) NS
AST (IU/l) 115 (130) 149 (120) NS
ALT (IU/l) 106 (117) 158 (121) NS
Alkaline phosphatase (IU/l) 290 (239) 247 (119) NS
ã-glutamyl transferase (IU/l) 118 (145) 149 (114) NS
Bilirubin (mg/dl) 2.2 (2.2) 3.3 (3) NS
Quantitative variables are expressed as mean (SD). Categorical variables are expressed as n (%).
PBC, primary biliary cirrhosis.
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acute and chronic infection in man.1 2 The
recent development of sensitive laboratory
techniques for determination of HGV RNA
sequences in clinical specimens has led to
intensive investigation of the frequency and
meaning of HGV infection in diVerent clinical
conditions. Despite many eVorts, however,
important aspects of the epidemiology and
pathogenicity of HGV infection and its role in
acute and chronic liver diseases still remain
obscure.
In the current study we investigated the
presence of HGV RNA infection in a large
series of patients with a variety of chronic liver
diseases and in a group of volunteer blood
donors living in the same geographical area.
The main demographic, epidemiological, clini-
cal, and histopathological features in HGV
infected and non-infected patients were ana-
lysed.
It is now clear that patients heavily exposed
to blood and blood products, such as haemo-
philiacs, thalassaemics, and liver transplanted
patients,6 10 13 21 22 as well as those at high risk of
parenteral exposure, such as patients on
haemodialysis23 24 and intravenous drug
users,3 25 have the highest prevalence of HGV
infection. These data suggest that parenteral
exposure plays an important role in the
transmission of HGV. This study showed,
however, that a substantial proportion of HGV
infected patients with chronic liver disease did
not have a history of overt parenteral exposure,
suggesting that HGV could also be transmitted
by other routes. Furthermore, irrespective of
the clinical or histological diagnosis, most of
these patients also had evidence of infection by
other parenterally transmitted hepatotropic
viruses, such as HCV,HBV, or both, suggesting
that HGV may also spread through non-
apparent parenteral exposure. Interestingly,
four of the nine patients coinfected with HGV
and HBV were male homosexuals and did not
have associated risk factors. This observation
suggests that HGV may be sexually transmit-
ted, as recently reported.25
Despite a similar epidemiological back-
ground, the prevalence of HGV infection in
patients with chronic hepatitis C observed in
this study was approximately two times higher
than that in those with hepatocellular carci-
noma, most of whom were also infected with
HCV. The reason for this diVerence is unclear.
One possible explanation could be that chronic
HGV infection may subside with time, leading
to clearance of HGVRNA, as seems to occur in
patients with haematological disorders6 and in
intravenous drug misusers infected with HIV.25
This is likely because the patients with cancer
were older and, possibly, had more long lasting
viral infection than those with chronic hepati-
tis. The observation that HGV RNA was
detected in young rather than in middle aged
blood donors, further supports this hypothesis.
Data on the pathogenic eVects of HGV are
controversial. HGV infection is the only agent
identified in some patients with acute sporadic
non-A, non-E hepatitis,2 idiopathic fulminant
hepatitis,7 8 or cryptogenic chronic liver
disease.14 Studies in blood donors2 and in
haemodialysis patients,4 23 however, have
clearly shown that HGV infection is frequently
found in subjects without clinical or biochemi-
cal evidence of liver disease. In a recent study in
haemodialysis patients, HGV infected patients
did not usually present with liver abnormalities
except if coinfected with other hepatotropic
viruses.24
Mild elevation of ALT is often found in
HGV infected blood donors.2 In this study, a
minimal elevation of ALT was observed in one
of the six blood donors in whom HGV RNA
was detected in serum, but this abnormality
was also observed in a similar proportion of
HGV non-infected donors and may be a
non-specific finding.
In agreement with previous observa-
tions,18 26 27 infection with HGV did not appear
to increase the severity of liver lesions in
patients with chronic liver disease resulting
from HBV or HCV infection. On the other
hand, there is increasing evidence indicating
that coexisting HGV infection does not appear
to modify the response to interferon in patients
with chronic hepatitis C.18 26 27 These data sup-
port the hypothesis that HGV coinfection does
not play a relevant role in the pathogenesis of
HBV or HCV induced chronic liver disease.
Further evidence against the pathogenicity of
HGV was recently provided by a study of
patients with acute post-transfusional hepatitis,
showing that combined infection with HGV
and HCV did not produce more severe hepati-
tis than infection with HCV alone.28
Although HGV infection often becomes
chronic, chronic hepatitis does not appear to
develop in subjects persistently infected with
HGV alone, as recently shown in patients with
acute non-A, non-E hepatitis.29 In the current
study, the prevalence of HGV RNA in patients
with chronic liver disease unrelated to HCV or
HBV infection, including patients with cryp-
togenic disease and patients with cryptogenic
cirrhosis and hepatocellular carcinoma, was
similar to that observed in healthy volunteer
blood donors and in patients with alcoholic
liver disease. Thus, HGV does not seem to be
involved in cryptogenic liver diseases in our
geographical area.
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